We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed at $47.79 in the latest trading session, marking a -3.73% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.27% for the day. Elsewhere, the Dow saw an upswing of 0.43%, while the tech-heavy Nasdaq appreciated by 0.37%.
Heading into today, shares of the company had lost 0.68% over the past month, lagging the Medical sector's gain of 6.54% and the S&P 500's gain of 1.85%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. In that report, analysts expect Hims & Hers Health, Inc. to post earnings of $0.09 per share. This would mark year-over-year growth of 50%. Meanwhile, our latest consensus estimate is calling for revenue of $581.61 million, up 44.84% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $0.6 per share and a revenue of $2.35 billion, demonstrating changes of +122.22% and +58.91%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 6.27% lower within the past month. Hims & Hers Health, Inc. currently has a Zacks Rank of #4 (Sell).
Investors should also note Hims & Hers Health, Inc.'s current valuation metrics, including its Forward P/E ratio of 82.99. This signifies a premium in comparison to the average Forward P/E of 31.96 for its industry.
Investors should also note that HIMS has a PEG ratio of 3.35 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical Info Systems industry stood at 3.36 at the close of the market yesterday.
The Medical Info Systems industry is part of the Medical sector. With its current Zacks Industry Rank of 75, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS - Free Report) closed at $47.79 in the latest trading session, marking a -3.73% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.27% for the day. Elsewhere, the Dow saw an upswing of 0.43%, while the tech-heavy Nasdaq appreciated by 0.37%.
Heading into today, shares of the company had lost 0.68% over the past month, lagging the Medical sector's gain of 6.54% and the S&P 500's gain of 1.85%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. In that report, analysts expect Hims & Hers Health, Inc. to post earnings of $0.09 per share. This would mark year-over-year growth of 50%. Meanwhile, our latest consensus estimate is calling for revenue of $581.61 million, up 44.84% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $0.6 per share and a revenue of $2.35 billion, demonstrating changes of +122.22% and +58.91%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 6.27% lower within the past month. Hims & Hers Health, Inc. currently has a Zacks Rank of #4 (Sell).
Investors should also note Hims & Hers Health, Inc.'s current valuation metrics, including its Forward P/E ratio of 82.99. This signifies a premium in comparison to the average Forward P/E of 31.96 for its industry.
Investors should also note that HIMS has a PEG ratio of 3.35 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical Info Systems industry stood at 3.36 at the close of the market yesterday.
The Medical Info Systems industry is part of the Medical sector. With its current Zacks Industry Rank of 75, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.